Organization
Fudan University (Xiamen Branch)
27 abstracts
Abstract
Baseline heterogeneity of myeloid and stroma cells to predict pCR, baseline lymph node (LN) metastasis, and 1-year EFS in locally advanced ESCC with neoadjuvant immunotherapy: Final results from a single-arm, phase II clinical trial (SEEK-01).Org: Fudan University (Xiamen Branch), Xiamen, China,
Abstract
Exploratory phase I study of HF1K16 for the treatment of patients with refractory/recurrent advanced glioma: Preliminary efficacy and mechanism as a monotherapy.Org: Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Zhejiang University, Hangzhou, China,
Abstract
Zimberelimab combined with concurrent chemoradiotherapy for patients with locally advanced cervical cancer: Early results of efficacy and safety.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Fudan University Zhongshan Hospital,
Abstract
Endoscopic surgery combined chemoradiotherapy and PD-1 blockade in patients with sinonasal mucosal melanoma.Org: Eye & ENT Hospital, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd., Shanghai, China; EENT Hospital,
Abstract
Economic analysis of combined multi-cancer detection blood test and usual care.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group, Burning Rock Biotech, Guangzhou, China,
Abstract
PD-1 inhibitors versus conventional therapies for adjuvant treatment of resected acral melanoma: A systematic review and meta-analysis.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer.Org: Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Shanghai Medical College, Fudan University,
Abstract
The overall survival analysis of FUTURE-C-PLUS: Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for advanced, immunomodulatory triple-negative breast cancer—An open-label, single-arm, phase 2 trial.Org: Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,
Abstract
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.Org: Fudan University (Xiamen Branch), Shanghai Cancer Center, Shanghai, China,
Abstract
ARID1A deficiency in triple-negative breast cancer induces adaptive immune resistance and sensitivity to immune checkpoint inhibitors.Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch),
Abstract
A 5-hydroxymethylcytosine-based noninvasive model for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma: The METHOD-2 study.Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd., Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, The First Medical Center,
Abstract
Development and validation of a non-invasive cfDNA targeted sequencing assay for early-stage hepatocellular carcinoma detection using cfDNA methylation and fragmentomics.Org: Singlera Genomics Ltd., Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch),
Abstract
Heterogeneous baseline immune cell infiltration landscape as a predictor of pathological complete response in locally advanced esophageal squamous cell carcinoma (ESCC) following neoadjuvant chemotherapy and immunotherapy: Results from a single-arm, phase II clinical trial (SEEK-01).Org: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch),
Abstract
Autologous cytotoxic T-cell receptor T cell therapy (SCG101) against hepatitis B surface antigen phase I/II trial for patients with advanced hepatitis B-related hepatocellular carcinoma.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Cornell University, National University Hospital, Department of Clinical Oncology, The Affiliated Cancer Hospital of Nanjing Medical University,
Abstract
A combinatorial model of plasma proteins and LDCT imaging and the diagnosis of pulmonary nodules.Org: Experimental Animal Center, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, West China Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).Org: Zhongda Hospital, Southeast University, School of Medicine, Zhejiang University, Hangzhou, China, University of Science and Technology of China, Fudan University (Xiamen Branch), Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Abstract
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Pattern of failure and re-irradiation for stereotactic radiotherapy treated brain metastases from non-small cell lung cancer (NSCLC).Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fudan University Shanghai Cancer Center,
Abstract
Prevalence and characteristics analysis of CDKN2A/B deletion in glioma.Org: Huashan Hospital Fudan University, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd.,
Abstract
CCT6A and triple-negative breast cancer metastasis: Activating the AKT/MDM2/P53 pathway.Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Fudan University (Xiamen Branch), Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Breast and Urinary Oncology,
Abstract
Phase I/II study to evaluate penpulimab combined with anlotinib and epirubicin in the first-line treatment of soft tissue sarcoma: Updated.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Ultra-sensitive baseline-informed MRD assay to predict prognosis outcomes in patients with resectable hepatocellular carcinoma.Org: Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Huidu Shanghai Medical Sciences, Ltd.,
Abstract
The efficacy and safety of toripalimab combined with sorafenib for unresectable hepatocellular carcinoma: An open-label, prospective, single-arm phase II study.Org: Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University,
Abstract
Analysis of the efficacy and safety of PD-1/PD-L1 inhibitors–based treatment in myxofibrosarcoma: A single-institution retrospective analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Effects of different immune microenvironment characteristics on effect of immune checkpoint inhibitors in solid tumors with TGFBR2 mutation.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Huashan Hospital Fudan University, Fudan University (Xiamen Branch), Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Technical performance of cancer detection and TOO identification of PanSeer7, a targeted bisulfite sequencing assay for non-invasive multi-cancer detection.Org: Singlera Genomics Ltd., Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai, China, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China, Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch),
Abstract
BIOMARKER CHANGES IN TAKAYASU ARTERITIS AFTER TOFACITINIB TREATMENT AND THE MOLECULAR SIGNATURE ASSOCIATED WITH DISEASE CHARACTERISTICSOrg: Zhongshan Hospital of Fudan University, Shanghai, China, Fudan University (Xiamen Branch), Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany, Shanghai Henlius Biotech, China National Biotec Group,